Title
|
|
|
|
Positron emission tomography in the management of nonsmall cell lung cancer
|
|
Author
|
|
|
|
|
|
Abstract
|
|
|
|
Positron emission tomography (PET) originally was a research tool for brain function and cardiac metabolism studies. In the past decade, metabolic imaging with PET has become an important new technique in the management of cancer patients. Although the structure-based imaging modalities like CT and MRI allow exquisite anatomic detail, their ability to correctly characterize tissues is limited by the fact that structural information alone does not always allow differentiation between malignant and benign lesions. Because PET relies on the detection of metabolic alterations observed in cancer cells, this examination yields data other than the associated structural characteristics. PET, therefore, allows the detection or monitoring of specific metabolic alterations that are not always associated with (or even precede) the anatomic changes. Lung cancer is likely the malignant tumor most extensively studied with PET. Most experience is gained in the characterization of indeterminate lung nodules and in staging of nonsmall cell lung cancer (NSCLC). |
|
|
Language
|
|
|
|
English
|
|
Source (journal)
|
|
|
|
Hematology and oncology clinics of North America. - Philadelphia, Pa, 1987, currens
|
|
Publication
|
|
|
|
Philadelphia, Pa
:
2004
|
|
ISSN
|
|
|
|
0889-8588
1558-1977
[online]
|
|
DOI
|
|
|
|
10.1016/S0889-8588(03)00152-7
|
|
Volume/pages
|
|
|
|
18
:1
(2004)
, p. 269-288
|
|
ISI
|
|
|
|
000189165400019
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|